# US 2025/0164482 A1 · Affinity filamentous material for lyme disease biomarker capture from biological samples

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0164482 A1
- Document ID: US20250164482A1
- Status: Published application
- Kind: A1
- Application number: 18/953,424
- Filed: 2024-11-20
- Published: 2025-05-22
- Earliest claimed: 2023-11-20
- Applicants: George Mason University
- Inventors: Alessandra Luchini KUNKEL; Lance Allen LIOTTA; Barbara BIRKAYA; Rocío Solange PRISBY; Sumaiya Safia IRFAN
- Web page: https://patentgrep.com/patent/US20250164482A1

## CPC

- G01N 33/56911: {Bacteria}
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- G01N 2333/20: from Spirochaetales (O), e.g. Treponema, Leptospira
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

An embodiment of the invention relates to a method for diagnosing Lyme disease, comprising: isolating a diagnostic composition from a biological sample, wherein the biological sample is urine or another bodily fluid, the diagnostic composition comprising a biomarker attributable to Borrelia strains, bound or complexed to an affinity molecule that is bound or complexed to a filamentous material; and analyzing isolated diagnostic composition using a mass spectrometry, an immunoassay, a protein sequencing, or other analytical methods to detect presence of Borrelia-derived biomarkers.

## Claims

### Claim 1

A method for diagnosing Lyme disease, comprising:
isolating a diagnostic composition from a biological sample, wherein the biological sample is urine or another bodily fluid, the diagnostic composition comprising a biomarker attributable to Borrelia strains, bound or complexed to an affinity molecule that is bound or complexed to a filamentous material; and
analyzing isolated diagnostic composition using a mass spectrometry, an immunoassay, a protein sequencing, or other analytical methods to detect presence of Borrelia-derived biomarkers.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the mass spectrometry analysis involves tandem mass spectrometry (MS/MS) for identification and quantification of Borrelia-derived peptides.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the immunoassay is an enzyme-linked immunosorbent assay (ELISA) designed to detect peptide markers bound to the filamentous material.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the protein sequencing is conducted using high-throughput sequencing technologies for comprehensive identification of Borrelia strain peptide markers.

### Claim 5 (depends on 1)

The method according to claim 1, further comprising comparing detected peptide markers with a reference database to confirm presence of one or more Borrelia strain indicative of Lyme disease.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the isolated composition is processed to remove non-specific proteins and impurities prior to analytical testing to enhance detection accuracy.

### Claim 7 (depends on 1)

The method of claim 1, wherein a weight ratio (% W/W) between a total amount of affinity molecule attached to the filamentous material is about 0.5 to 2%.

### Claim 8 (depends on 1)

The method of claim 1, wherein isolation of the said composition is contacting the filamentous material with a volume of a biological sample to allow the affinity molecule to capture one or more biomarkers present in the biological sample in a suitable condition, eluting captured biomarkers; and wherein the said method is a non-invasive process.

### Claim 9 (depends on 1)

The method of claim 1, wherein the filamentous material is a non-imbibing material.

### Claim 10 (depends on 8)

The method of claim 8, wherein the suitable condition comprises pH of the biological sample.

### Claim 11 (depends on 1)

The method of claim 1, wherein the biological sample is not preserved in a refrigerated condition before contacting the filamentous material.

### Claim 12 (depends on 1)

The method of claim 1, wherein the filamentous material is heated at a temperature about its glass transition temperature to allow its functionalization with one or more affinity molecule.

### Claim 13

A diagnostic composition comprising: a biomarker derived from Borrelia strains; wherein the biomarker is bound or complexed to an affinity molecule; and the affinity molecule is bound or complexed to a filamentous material.

### Claim 14 (depends on 13)

The diagnostic composition of claim 13, wherein the affinity molecule comprises salts and/or solvates.

### Claim 15 (depends on 13)

The diagnostic composition of claim 13, wherein the composition is configured to detect a biomarker indicative of lyme disease.

### Claim 16 (depends on 13)

The composition of claim 13, wherein the biomarker includes a protein, polypeptide, nucleic acids, lipids, antigens, carbohydrates, or glycanproteins, exososomes, extracellular vesicles unambiguously attributable to pathogenic Borrelia strains.

### Claim 17 (depends on 13)

The composition of claim 13, wherein the affinity molecule is selected from the group consisting of dyes, metal ions, drugs, antibodies, recombinant antibodies, co-enzymes, vitamins, proteins, peptides, aptamers, receptor ligands, and lectins.

### Claim 18 (depends on 13)

The diagnostic composition of claim 13, wherein the affinity molecule comprises a hydrogel.

### Claim 19 (depends on 13)

The diagnostic composition of claim 13, wherein the filamentous material is selected from a natural or a synthetic fibre.

### Claim 20 (depends on 13)

The diagnostic composition of claim 13, wherein the filamentous material comprises a polymer selected from nylon-6 and/or polyamide.
